In the present study, IL-9 was initially identified as a strong regulator of blood glucose in diabetic db/db mice through a hydrodynamic gene delivery screening effort. IL-9 belongs to the common gamma-chain binding cytokine family and has classically been linked to asthma and type 2 immune responses. Alongside the very clear dosing effects of mouse IL-9 on fasting blood glucose, the more classical effects of IL-9, including IL-5 plasma increases and eosinophilia, were also observed in the db/db mice. An expansion of epididymal white adipose tissue macrophages was shown with IL-9-, but not IL-5 dosing. Inhibition of endogenous IL-5, with an anti-IL5 mAb, attenuated the IL-9 effects on eosinophils but not macrophages. Interestingly, suppression of glucagon levels following IL-9 dosing was a general observation in several diabetic mouse studies. The addition of anti-IL-5 mAb to IL-9 dosing did not affect glucagon levels in the db/db mouse model, and an association between eosinophil/macrophage changes and blood glucose could not be established. To examine the translation of these interesting IL-9 effects to higher species, a recombinant protracted human IL-9 dosed to low streptozotocin induced diabetic mini-pigs (2-week study) , showed increased numbers of circulating eosinophils, but no significantly reduced levels of glucagon or plasma glucose. Finally, an 11-week treatment study in type 2 diabetic cynomolgus monkeys was performed. Eosinophilia was observed as an indicator of IL-9 receptor engagement, but several glycaemic parameters and glucagon levels were unaffected throughout the study. Conclusion: The pronounced glycaemic effects observed for IL-9 in a diabetic mouse model was not found in diabetic minipigs and non-human primates highlighting the complexity and need for further studies of the translation of immuno-metabolic phenotypes.


T.Guo: Employee; Novo Nordisk A/S. K.S.Frederiksen: Employee; Novo Nordisk A/S. E.Straarup: Employee; Novo Nordisk A/S. J.Lindroos christensen: Employee; Novo Nordisk A/S. G.Bolt: Employee; Novo Nordisk A/S. P.Lisby nørby: Employee; Novo Nordisk A/S. W.Zhe: Employee; Novo Nordisk A/S. T.A.Pedersen: Employee; Novo Nordisk A/S, Stock/Shareholder; Novo Nordisk A/S. M.Ferreras: Employee; Novo Nordisk A/S. K.Sass-ørum: Employee; Novo Nordisk A/S.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at